| abstract |
The invention pertains to a human-derived T cell receptor (mhTCR) that, compared to the human wild-type T cell receptor (wtTCR), bears mutations at certain sites of the constant TCR beta region 2 (Cβ2) or the constant TCR beta region 1 (Cβ1) and the constant TCR alpha region (Cα). The presence of these mutations renders the mhTCR to be expressed in higher numbers on the cell surface compared to the wtTCR. Furthermore, the mhTCR of the invention shows a low immunogenic effect, since the number of mutations is low. |